Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 57.73% and Operating profit at 9.68% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.62
2
Flat results in Dec 24
3
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.53%
0%
-14.53%
6 Months
88.93%
0%
88.93%
1 Year
-2.51%
0%
-2.51%
2 Years
-11.84%
0%
-11.84%
3 Years
134.9%
0%
134.9%
4 Years
-13.04%
0%
-13.04%
5 Years
-12.83%
0%
-12.83%
Adocia SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
57.73%
EBIT Growth (5y)
9.68%
EBIT to Interest (avg)
-12.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.78
Tax Ratio
16.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-139.97
EV to EBIT
-12.92
EV to EBITDA
-13.55
EV to Capital Employed
-36.25
EV to Sales
13.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
2.10
11.40
-81.58%
Operating Profit (PBDIT) excl Other Income
0.00
-18.30
100.00%
Interest
0.00
2.90
-100.00%
Exceptional Items
0.00
-1.80
100.00%
Consolidate Net Profit
0.00
-6.90
100.00%
Operating Profit Margin (Excl OI)
0.00%
-1,643.20%
164.32%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -81.58% vs 714.29% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 100.00% vs 69.74% in Dec 2022
About Adocia SA 
Adocia SA
Pharmaceuticals & Biotechnology
Adocia SA, also known as Adocia, is a France-based company engaged in the biotechnology business sector. It specializes in the research and development of biotherapy products used in tissue regeneration and for treating chronic diseases. The Company develops a BioChaperone Platform used for therapeutic protein delivery in regenerative medicine and chronic disease areas, such as wound Healing, diabetes, ulcers and monoclonal antibody creation. The Company completed two Phases I and II studies of the formulation of human insulin, two Phases I and II studies of insulin lispro and one Phase I/II on a combination of insulin glargine, the basal insulin and insulin lispro, an insulin analog. Adocia also undertaken the activities in the field of formulation of monoclonal antibodies which are molecules for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Company Coordinates 
Company Details
115 avenue Lacassagne , LYON None : 69003
Registrar Details






